Evidence map›Paper›PMID 29563509›Full record

ArticleScientific reports2018

Neuroprotective effect of dexmedetomidine in a murine model of traumatic brain injury.

Jin Wu, Todd Vogel, Xiang Gao, Bin Lin, Charles Kulwin, Jinhui Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Association of early dexmedetomidine exposure with brain injury biomarker levels following moderate - Severe traumatic brain injury: A TRACK-TBI study.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Dexmedetomidine in the Treatment of Depression: An Up-to-date Narrative Review.Clinical practice and epidemiology in mental health : CP & EMH · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Jin WuDepartment of Orthopaedics, the Affiliated Southeast Hospital of Xiamen University, Zhangzhou, China.
Todd VogelDepartment of Neurosurgery, Indiana University, Indianapolis, IN, USA.
Xiang GaoSpinal Cord and Brain Injury Research Group, Stark Neuroscience Research Institute, Indianapolis, IN, USA.
Bin LinDepartment of Orthopaedics, the Affiliated Southeast Hospital of Xiamen University, Zhangzhou, China.
Charles KulwinDepartment of Neurosurgery, Indiana University, Indianapolis, IN, USA.
Jinhui ChenDepartment of Neurosurgery, Indiana University, Indianapolis, IN, USA. chen204@iupui.edu.
Indiana University – Purdue University Indianapolis · USXiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

No FDA approved pharmacological therapy is available that would reduce cell death following traumatic brain injury (TBI). Dexmedetomidine (Dex) is a highly selective agonist of alpha-2 adrenergic receptors and has demonstrated neuroprotective effects in hippocampal slice cultures undergoing direct impact. However, no one has tested whether Dex, in addition to its sedative action, has neuroprotective effects in an animal model of TBI. Thus, in the present study, we investigated the effects of Dex on an animal model of TBI. Mice received different doses of Dex (1, 10, or 100 µg/kg bodyweight, n = 10 each group) or saline as control at 1 hour and 12 hours following TBI. The mice treated with Dex lost less cortical tissue than the control mice. Further analysis found that Dex treatment reduced cell death in the cortex and the hippocampus measured by Fluoro-Jade B (FJB) staining, prevented axonal degeneration detected by immunostaining with antibody against β-amyloid precursor protein (β-APP), and protected synapses from elimination with synaptophysin staining. Taken together, in an in vivo murine model of TBI, Dex at the dose of 100 µg/kg not only prevented tissue lesion and cell death, but also reduced axonal injury and synaptic degeneration caused by TBI.

Indexed as

Brain Injuries, TraumaticCerebral CortexHippocampusAnimalsDexmedetomidineDisease Models, AnimalMaleMiceNeuroprotective AgentsDexmedetomidineNeuroprotective Agents

Identifiers

PMID29563509
PMCPMC5862953
OpenAlexW2806470882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.